Achilles EXPII

Accurate fracture risk assessment, comfortable for your patients and convenient for operators.


The Achilles EXPII bone ultrasonometer helps you protect the vitality of your patients by making fracture risk assessment accessible, comfortable and convenient. The exam is quick and comfortable for your patients, and its user-friendly design makes it easy for your staff to operate, with no formal certification required. The osteoporotic fracture risk assessment provided by Achilles EXPII closely matches prevalence as defined by central DXA1, 2, 3 while being fast and affordable. Its high negative predictive value — 97 percent for 50- to 59-year-old Caucasian women —makes Achilles EXPII especially useful for discriminating between those not at risk for fracture and those in need of further evaluation by central DXA.4
Additionally, Achilles EXPII has proven long-term precision, making it useful for monitoring bone changes.5,6,7

Benefits

Achilles EXPII bone ultrasonometer offer you the following benefits:

  • CERTAINITY

    High Negative Predictive Value.

    Osteoporotic fracture risk assessment as discriminating as DXA at the hip and spine. High negative predictive value.1 Clinicians can be use Achilles EXPII in initial osteoporotic assessment before referring to a DXA scan.

  • COMFORT

    A quick and comfortable exam.

    Bone assessments take just a few minutes. Your patients sit comfortably during the pain-free exam—no messy gels required. Moreover, the unit emits no ionizing radiation.

  • CONVENIENCE

    Efficient customizable workflow.

    Achilles units are portable and affordable. When combined with the quick exam time, these features help enable you to reach more patients. Furthermore, the user-friendly Achilles EXPII requires no special room and no formal certification. Results are concise, convenient to print on the spot and easy for the staff to interpret.

Related Products

Resources
  1. Krieg M-A, Barkmann R, Gonnelli S, et al. Quantitative Ultrasound in the Management of Osteoporosis: The 2007 ISCD Official Positions. J Clin Densitom: Assessment of Skeletal Health. 2008; 11 (1): 163-187.
  2. Simon D, Boring III JR. Chap. 6: Sensitivity, Specificity, and Predictive Value. In: HK Walker, WD Hall, JW Hurst, ed. Clinical Methods: The History, Physical, and Laboratory Examinations, 3rd edition. Boston: Butterworths; 1990.
  3. Gonnelli S, Cepollaro C, Pondrelli C, Martini S, Rossi S, Gennari C. Ultrasound parameters in osteoporotic patients treated with salmon calcitonin: A longitudinal study. Osteoporos Int. 1996; 6 (4): 303-307.
  4. Giorgino R, Paparella AP, Lorusso D, Mancuso S. Effects of oral alendronate treatment and discontinuance on ultrasound measurements of the heel in postmenopausal osteoporosis. North American Menopausal Society, September 1996.
  5. Gonnelli S, Cepollaro C, Montagnani A, et al. Heel ultrasonography in monitoring alendronate therapy: a four-year longitudinal study. Osteoporos Int. 2002; 13 (5): 415-421.